Potential Metabolic Biomarkers to Identify Interstitial Lung Abnormalities

Tan, Yong; Jia, Dongmei; Zhou, Lin; Guo, Baosheng; He, Bing; Lü, Cheng; Xiao, Cheng; Liu, Zhongdi; Zhao, Ning; Bian, Zhaoxiang; Zhang, Ge; Zhang, Guoqing; Liu, Xinru; Lü, Aiping

doi:10.3390/ijms17071148

Cited by 12 publications

(8 citation statements)

References 57 publications

(61 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LPC levels were elevated in serum samples from IPF patients as determined by ultra-high-performance liquid chromatography coupled to high-resolution mass spectrometry, and it was suggested that LPC could serve as a biomarker for IPF [249]. However, metabolomics analysis of peripheral blood samples from abnormal interstitial lung patients revealed downregulation of 1-acyl LPC but upregulation of PC, PA, and PE suggesting potential activation of lipid metabolizing enzymes during the development of interstitial lung abnormalities [250]. However, LPA, the major lysolipid linked to development of IPF, was not identified in the analysis.…”

Section: Lysophospholipids and Lysophospholipids Metabolizing Enzymesmentioning

confidence: 99%

Lipid Mediators Regulate Pulmonary Fibrosis: Potential Mechanisms and Signaling Pathways

Suryadevara

Ramchandran

Kamp

et al. 2020

IJMS

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease of unknown etiology characterized by distorted distal lung architecture, inflammation, and fibrosis. The molecular mechanisms involved in the pathophysiology of IPF are incompletely defined. Several lung cell types including alveolar epithelial cells, fibroblasts, monocyte-derived macrophages, and endothelial cells have been implicated in the development and progression of fibrosis. Regardless of the cell types involved, changes in gene expression, disrupted glycolysis, and mitochondrial oxidation, dysregulated protein folding, and altered phospholipid and sphingolipid metabolism result in activation of myofibroblast, deposition of extracellular matrix proteins, remodeling of lung architecture and fibrosis. Lipid mediators derived from phospholipids, sphingolipids, and polyunsaturated fatty acids play an important role in the pathogenesis of pulmonary fibrosis and have been described to exhibit pro- and anti-fibrotic effects in IPF and in preclinical animal models of lung fibrosis. This review describes the current understanding of the role and signaling pathways of prostanoids, lysophospholipids, and sphingolipids and their metabolizing enzymes in the development of lung fibrosis. Further, several of the lipid mediators and enzymes involved in their metabolism are therapeutic targets for drug development to treat IPF.

show abstract

Section: Lysophospholipids and Lysophospholipids Metabolizing Enzymesmentioning

confidence: 99%

Lipid Mediators Regulate Pulmonary Fibrosis: Potential Mechanisms and Signaling Pathways

Suryadevara

Ramchandran

Kamp

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…It is the biomarker discoveries and the corresponding biological insights that enable metabolomics to change our understanding of the development of many chronic diseases. Up to now, metabolomics has found applications in many chronic metabolic disorders, such as diabetes, lung disease, neurodegenerative disease, cancer, hypertension, and cardiovascular diseases [3,4,5]. In recent years, metabolomics have gained popularity in the orthopedic field, including osteonecrosis, osteoarthritis, ankylosing spondylitis, bone tumors and osteoporosis [6,7,8,9].…”

Section: Introductionmentioning

confidence: 99%

Metabolomics and Its Application in the Development of Discovering Biomarkers for Osteoporosis Research

Jiang

Guan

et al. 2016

IJMS

Self Cite

View full text Add to dashboard Cite

Osteoporosis is a progressive skeletal disorder characterized by low bone mass and increased risk of fracture in later life. The incidence and costs associated with treating osteoporosis cause heavy socio-economic burden. Currently, the diagnosis of osteoporosis mainly depends on bone mineral density and bone turnover markers. However, these indexes are not sensitive and accurate enough to reflect the osteoporosis progression. Metabolomics offers the potential for a holistic approach for clinical diagnoses and treatment, as well as understanding of the pathological mechanism of osteoporosis. In this review, we firstly describe the study subjects of osteoporosis and bio-sample preparation procedures for different analytic purposes, followed by illustrating the biomarkers with potentially predictive, diagnosis and pharmaceutical values when applied in osteoporosis research. Then, we summarize the published metabolic pathways related to osteoporosis. Furthermore, we discuss the importance of chronological data and combination of multi-omics in fully understanding osteoporosis. The application of metabolomics in osteoporosis could provide researchers the opportunity to gain new insight into the metabolic profiling and pathophysiological mechanisms. However, there is still much to be done to validate the potential biomarkers responsible for the progression of osteoporosis and there are still many details needed to be further elucidated.

show abstract

“…The results showed that the large scale sample analysis has no signi cant effect on the reliability of the data. 20…”

Section: Testing With the Gc-ms Methodsmentioning

confidence: 99%

“…\The linear retention indices of all components were determined by homologous n-alkanes (C 10 -C 40 ).These components were identi ed by comparing with the mass spectra of NIST05 and NIST05S. 20…”

Section: Gc-ms Analysismentioning

confidence: 99%

Activation of protein kinase A signaling and inhibitions of glycine/glutathione biosynthesis involves in the transition from prediabetes to diabetes based on metabolomics data analysis

Zhao

Zhan

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Metabolomics is expected to identify potential metabolites and related pathways, and further reveal the underlying mechanisms of the transition from prediabetes to diabetes. In this study, a metabolomics-based gas chromatography-mass spectrometry (GC-MS) technique was used for demonstrating the serum metabolic profiles among healthy, prediabetes, and diabetes at fasting state and 2h oral glucose tolerance test (2h OGTT) state. With Ingenuity Pathway Analysis (IPA) tool, the comparative analysis showed no significant differences in the pathway analysis (P > 0.05) between prediabetes and diabetes at either fasting state or 2h OGTT state. The self-comparative analysis demonstrated the glycine/glutathione biosynthesis in diabetes were more inhibited than that in prediabetes or healthy control at 2h OGTT state compared with fasting state (P<0.05). In addition, the protein kinase A signaling pathway in prediabetes or diabetes was significantly inhibited more than that in healthy control (P<0.05). Therefore, the glycine/glutathione biosynthesis and protein kinase A signaling could differentiate the diabetic subjects from the prediabetic and healthy control subjects, and may involve in prediabetes transition to diabetes. This study provided more metabolomics information for the transition from prediabetes to diabetes.

show abstract

Potential Metabolic Biomarkers to Identify Interstitial Lung Abnormalities

Cited by 12 publications

References 57 publications

Lipid Mediators Regulate Pulmonary Fibrosis: Potential Mechanisms and Signaling Pathways

Lipid Mediators Regulate Pulmonary Fibrosis: Potential Mechanisms and Signaling Pathways

Metabolomics and Its Application in the Development of Discovering Biomarkers for Osteoporosis Research

Activation of protein kinase A signaling and inhibitions of glycine/glutathione biosynthesis involves in the transition from prediabetes to diabetes based on metabolomics data analysis

Contact Info

Product

Resources

About